At Parallel Profile, Cather is working with Cloud Pharmaceuticals, Mercury Data Science, Vanderbilt, Nashville BioSciences and others to mine literature, databases and EMRs in order to identify drugs that can be immediately repurposed to make patients stronger, more able to fight off a potential COVID-19 infection. Their curated research aims to uncover drugs that will help boost the immune system, increase ATP in the mitochondria, reduce inflammation in the lower lungs, slow the viral replication pathway, and increase gas exchange in the lungs. With the use of AI, Cather says “answer could come within a month” and be continually updated against infected patient EMR and genomics data.